Status:
WITHDRAWN
IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors
Lead Sponsor:
Portsmouth Hospitals NHS Trust
Collaborating Sponsors:
Vifor Pharma
Conditions:
Hyperkalemia
Eligibility:
All Genders
18+ years
Brief Summary
There are limited data regarding the burden of hyperkalaemia in patients attending emergency departments (ED) or who are hospitalised (excluding those already receiving dialysis). Renin-angiotensin-al...
Detailed Description
Research questions: In an adult population of patients who are hospitalised or attending the emergency department (and not receiving dialysis) with hyperkalaemia: 1. How does hyperkalaemia impact on...
Eligibility Criteria
Inclusion
- Patients in ED or inpatients with at least 1 blood test with a potassium level of ≥5.5 mmol/l
- Receiving RAASi.
- Aged 18 and above.
- Able to provide informed consent or consent provided by consultee in those unable to consent for themselves.
Exclusion
- Patients already receiving dialysis prior to the episode of hyperkalaemia.
- For patients considered for postal consent: known cognitive impairment, learning difficulties or brain injury or those who had transient cognitive impairment, delirium or required urgent deprivation of liberty form completion during inpatient stay or in the previous 12 months prior to hyperkalaemia episode.
Key Trial Info
Start Date :
July 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 12 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04510792
Start Date
July 12 2021
End Date
July 12 2021
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital
Portsmouth, Hampshire, United Kingdom, PO6 3LY